行情

QURE

QURE

Uniqure
NASDAQ

实时行情|Nasdaq Last Sale

48.54
+1.63
+3.47%
已收盘, 16:00 09/17 EDT
开盘
46.90
昨收
46.91
最高
48.75
最低
46.34
成交量
39.31万
成交额
--
52周最高
82.49
52周最低
21.98
市值
21.10亿
市盈率(TTM)
-17.6824
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

QURE 新闻

  • New coverage - healthcare
  • Seeking Alpha - Article.5天前
  • Mizuho Initiates Coverage On uniQure with Buy Rating, Announces $67 Price Target
  • Benzinga.5天前
  • uniQure prices stock offering at $46; shares down 2% premarket
  • seekingalpha.09/06 15:30
  • 16 Healthcare Stocks Moving In Friday's Pre-Market Session
  • Benzinga.09/06 12:31

更多

所属板块

生物技术和医学研究
+0.26%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

QURE 简况

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-061 for Hemophilia B, AMT-130 for Huntington's disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.
展开

Webull提供Uniqure NV的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。